세계 일회용 비강 스프레이 장치 시장은 2023년에 3억 3,550만 달러에 달했습니다, 2033년에는 5억 3,710만 달러에 달할 것으로 예상되며, 예측 기간인 2025년부터 2033년까지 6.5%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.
1회용 비강 스프레이 장치는 1회 분량의 약물이 미리 계량된 단위 용량 장치로, 응급 상황에서 유용하게 사용할 수 있습니다. 기존에 주사로 투여하던 오피오이드나 나록손과 같이 전문적 훈련이나 의료 전문가에 대한 즉각적인 접근 없이도 환자나 간병인이 생명을 구할 수 있는 약물을 투여할 수 있습니다.
성장 촉진요인 및 저해요인
알레르기성 비염의 유병률 증가
세계 일회용 비강 점비 장치 시장은 코막힘, 재채기, 가려움증을 유발하는 만성 질환인 알레르기성 비염의 유병률 증가로 인해 확대되고 있습니다. 이러한 장치는 정확한 투약과 부작용을 최소화할 수 있는 편리하고 정확한 방법을 제공함으로써 질환을 관리하는 데 필수적인 역할을 합니다. 알레르기 비염에 대한 인식이 높아지고 환자들이 보다 효율적인 치료법을 찾게 되면서 첨단 비강 점안제에 대한 수요는 지속적으로 증가하고 있습니다. 혁신적인 제제의 가용성은 이러한 추세를 더욱 촉진하고 있습니다.
예를 들어, World Allergy Organization Journal에 따르면 알레르기성 비염은 전 세계적으로 4억 명 이상이 앓고 있으며, 유병률은 성인의 경우 10%-30%, 소아의 경우 40% 이상의다.
따라서, 1회용 비강 점적 장치는 사용 편의성, 정확한 투약, 빠른 작용으로 알레르기 비염 증상 관리에 이상적입니다. 이러한 장치의 광범위한 보급은 이러한 장치에 대한 수요를 촉진하고 첨단 약물 제제 및 장치 기술에 대한 기술 혁신과 투자를 촉진하여 시장 확대에 박차를 가하고 있습니다.
환자에 의한 오남용 및 부적절한 투여의 위험
세계 1회용 비강 점적 장치 시장은 환자의 오용 및 부적절한 투여의 위험으로 인해 문제에 직면해 있습니다. 이러한 디바이스는 정확한 취급 및 적용 기술이 필요하기 때문에 특히 소아 및 노년층과 같이 디바이스에 익숙하지 않은 환자에게는 어려움이 있을 수 있습니다. 환자 교육 및 훈련 프로그램의 부재는 이러한 문제를 더욱 악화시켜 용량 부족과 낭비를 초래할 수 있습니다. 또한, 1회용 장치는 다회용 장치에 비해 의료 폐기물을 더 많이 발생시키는 것으로 알려져 환경에 대한 관심이 높아지고 폐기물 관리 정책이 엄격한 지역에서 채택을 저해하는 요인으로 작용하고 있습니다. 이러한 문제들은 시장 성장을 저해하고 있으며, 더 나은 설계 혁신과 환자 지원 이니셔티브의 필요성을 강조하고 있습니다.
The global single-dose nasal spray devices market reached US$ 335.5 million in 2023 and is expected to reach US$ 537.1 million by 2033, growing at a CAGR of 6.5% during the forecast period 2025-2033.
Single-dose nasal sprays are unit-dose devices that contain a single, pre-measured dose of medication, making them useful in emergency settings. They allow patients or caregivers to administer life-saving medications without requiring specialized training or immediate access to healthcare professionals, such as opioids or naloxone, which are traditionally administered via injection.
Market Dynamics: Drivers & Restraints
Increasing Prevalence of Allergic Rhinitis
The global single-dose nasal spray devices market is growing due to the rising prevalence of allergic rhinitis, a chronic condition causing nasal congestion, sneezing, and itching. These devices offer a convenient, targeted method for precise dosing and minimal side effects, making them essential for managing the condition. As awareness of allergic rhinitis increases and patients seek more efficient treatment options, demand for advanced nasal spray devices continues to rise. The availability of innovative formulations further supports this trend.
For instance, according to World Allergy Organization Journal, Globally, allergic rhinitis affects more than 400 million people, with prevalence rates between 10% and 30% among adults and over 40% among children.
Hence, Single-dose nasal spray devices are ideal for managing allergic rhinitis symptoms due to their ease of use, precise dosing, and rapid action. Their widespread prevalence drives demand for these devices, encouraging innovation and investments in advanced drug formulations and device technologies, thereby fueling market expansion.
Risk of Misuse and Improper Administration by Patients
The global single-dose nasal spray device market faces challenges due to the risk of misuse and improper administration by patients. These devices require precise handling and application techniques, which can be challenging for patients unfamiliar with them, especially in pediatric and elderly populations. The lack of robust patient education and training programs further exacerbates this issue, leading to potential underdosing or wastage. Additionally, single-dose devices are perceived to generate more medical waste than multi-dose alternatives, raising environmental concerns and deterring adoption in regions with strict waste management policies. These challenges hinder market growth and underscore the need for better design innovation and patient support initiatives.
The global single-dose nasal spray devices market is segmented based on product type, material type, end user and region.
Liquid Nasal Sprays segment is expected to dominate the single-dose nasal spray devices market share
The liquid nasal sprays segment holds a major portion of the single-dose nasal spray devices market share and is expected to continue to hold a significant portion of the single-dose nasal spray devices market share during the forecast period.
Liquid nasal sprays are a key segment in the global single-dose nasal spray devices market due to their widespread use in various therapeutic areas, including allergic rhinitis, sinusitis, and emergency treatments like opioid overdose reversal. These sprays are preferred for their rapid onset of action, precision dosing, and ease of use, making them ideal for home-based and outpatient care. Advancements in liquid formulation technology have improved the stability and bioavailability of active ingredients, driving demand for innovative single-dose devices. The increasing adoption of liquid nasal sprays for vaccines and biologics further positions them as a key segment in the market.
Hospitals segment is the fastest-growing segment in single-dose nasal spray devices market share
The hospitals segment is the fastest-growing segment in the single-dose nasal spray devices market share and is expected to hold the market share over the forecast period.
Hospitals are driving the global single-dose nasal spray devices market growth due to their precision, ease of use, and effectiveness in acute care scenarios. These devices are ideal for emergency departments and critical care units, where timely intervention is crucial. Hospitals are often the first point of contact for patients with chronic conditions, leading to the prescription and adoption of single-dose nasal sprays for ongoing treatment. The growing emphasis on infection control in healthcare facilities further bolsters the demand for single-dose devices, as they reduce the risk of cross-contamination compared to multi-dose alternatives. As hospitals adopt advanced drug delivery technologies, their role in shaping the market trajectory continues to expand.
North America is expected to hold a significant position in the single-dose nasal spray devices market share
North America holds a substantial position in the single-dose nasal spray devices market and is expected to hold most of the market share due to the FDA approvals, product launches, high prevalence of respiratory and allergic conditions, as well as its well-established healthcare infrastructure. The region's focus on self-care and home-based treatments, coupled with widespread patient awareness, drives demand for these devices. Regulatory approvals and investment from leading pharmaceutical companies contribute to the region's growth. Government initiatives to combat opioid overdoses have also accelerated the adoption of single-dose nasal sprays for emergency treatments.
For instance, in August 2024, The U.S. FDA has approved neffy, an epinephrine nasal spray, for emergency treatment of Type I allergic reactions in adult and pediatric patients weighing at least 30 kilograms. Neffy is a single-dose nasal spray used to treat anaphylactic episodes. If symptoms persist or worsen, a second dose may be administered using a new nasal spray. Patients may need emergency medical assistance for monitoring and treatment if further treatment is needed.
Europe is growing at the fastest pace in the single-dose nasal spray devices market
Europe holds the fastest pace in the single-dose nasal spray devices market and is expected to hold most of the market share due to the chronic respiratory diseases, aging populations, and environmental allergen exposure. Advanced healthcare systems, patient-friendly treatment options, and a preference for minimally invasive therapies have boosted the adoption of these products. Strong regulatory frameworks and supportive policies for drug delivery innovations encourage market growth. Europe's commitment to sustainability has led to the development of eco-friendly and biodegradable nasal spray devices, aligning with consumer preferences. Europe's emphasis on preventive healthcare and high-quality medical products further strengthens its market position.
For instance, according to article published in ERS, the UK experiences 585,000 respiratory disease diagnoses annually, with half due to asthma and COPD. IPF prevalence is double previous estimates. Nearly 1 in 5 of the population has a lung disease diagnosis, with the highest prevalence in the North-West and South-West of England. This widespread prevalence also drives innovation and adoption of advanced single-dose nasal sprays for chronic and acute respiratory disease management, contributing to the overall growth of the market in Europe and beyond.
The major global players in the single-dose nasal spray devices market include Aptar Pharma, Nemera, BD (Becton, Dickinson and Company), H&T Presspart, Bespak by Recipharm, Rexam Healthcare Packaging, Silgan Dispensing Systems, West Pharmaceutical Services, Inc, Gerresheimer AG, 3M Drug Delivery Systems and among others.
Emerging Players
The emerging players in the single-dose nasal spray devices market include Portal Instruments, E3D (Engineered 3D), Medicon Pharma, Perlen Packaging and among others.
The global single-dose nasal spray devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
LIST NOT EXHAUSTIVE